|
Cayman Islands
(State or Other Jurisdiction of Incorporation or Organization) |
| |
6770
(Primary Standard Industrial Classification Code Number) |
| |
(I.R.S. Employer Identification Number) |
|
|
Alexander D. Lynch, Esq.
Weil, Gotshal & Manges LLP 767 Fifth Avenue New York, NY 10153 Tel: (212) 310-8000 Fax: (212) 310-8007 |
| |
Paul D. Tropp, Esq.
Christopher Capuzzi, Esq. Ropes & Gray LLP 1211 Avenue of the Americas New York, New York 10036 Tel: (212) 596-9000 Fax: (212) 596-9090 |
|
|
Large accelerated filer ☐
|
| |
Accelerated filer ☐
|
| |
Non-accelerated filer ☒
|
| |
Smaller reporting company ☒
|
| |
Emerging growth company ☒
|
|
| | |
Per Share
|
| |
Total
|
| ||||||
Public offering price
|
| | | $ | 10.00 | | | | | $ | 350,000,000 | | |
Underwriting discounts and commissions(1)
|
| | | $ | 0.55 | | | | | $ | 19,250,000 | | |
Proceeds, before expenses, to us
|
| | | $ | 9.45 | | | | | $ | 330,750,000 | | |
| Deutsche Bank Securities | | |
J.P. Morgan Securities
|
| |
Goldman Sachs & Co.
|
|
| Northland Securities | | | | | |
Siebert Williams Shank
|
|
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 43 | | | |
| | | | 44 | | | |
| | | | 45 | | | |
| | | | 84 | | | |
| | | | 88 | | | |
| | | | 89 | | | |
| | | | 92 | | | |
| | | | 93 | | | |
| | | | 100 | | | |
| | | | 136 | | | |
| | | | 150 | | | |
| | | | 154 | | | |
| | | | 157 | | | |
| | | | 175 | | | |
| | | | 184 | | | |
| | | | 194 | | | |
| | | | 194 | | | |
| | | | 194 | | | |
| | | | F-1 | | |
| | |
January 8, 2021
|
| |||
| | |
Actual
|
| |||
Balance Sheet Data:
|
| | |||||
Total assets
|
| | | $ | 56,952 | | |
Total liabilities
|
| | | $ | 40,809 | | |
Working capital
|
| | | $ | (15,809) | | |
Value of ordinary shares that may be redeemed in connection with our initial business combination ($10.00 per share)
|
| | | $ | — | | |
Shareholder’s equity
|
| | | $ | 16,143 | | |
| | |
Without
Over-Allotment Option |
| |
Over-Allotment
Option Fully Exercised |
| ||||||
Gross proceeds | | | | | | | | | | | | | |
Gross proceeds from shares offered to public(1)
|
| | | $ | 350,000,000 | | | | | $ | 402,500,000 | | |
Gross proceeds from private placement shares offered in the private placement
|
| | | | 9,000,000 | | | | | | 10,050,000 | | |
Total gross proceeds
|
| | | $ | 359,000,000 | | | | | $ | 412,500,000 | | |
Offering expenses(2) | | | | | | | | | | | | | |
Underwriting commissions (2.0% of gross proceeds from shares offered to public, excluding deferred portion)(3)(4)
|
| | | $ | 7,000,000 | | | | | $ | 8,050,000 | | |
Legal fees and expenses
|
| | | $ | 250,000 | | | | | $ | 250,000 | | |
Accounting fees and expenses
|
| | | | 90,250 | | | | | | 90,250 | | |
SEC Expenses
|
| | | | 43,913 | | | | | | 43,913 | | |
Financial Industry Regulatory Authority (“FINRA”) Expenses
|
| | | | 43,625 | | | | | | 43,625 | | |
Travel and road show
|
| | | | 5,000 | | | | | | 5,000 | | |
Directors and officers insurance(5)
|
| | | | 250,000 | | | | | | 250,000 | | |
NYSE listing and filing fees
|
| | | | 85,000 | | | | | | 85,000 | | |
Miscellaneous expenses
|
| | | | 132,212 | | | | | | 132,212 | | |
Total offering expenses (other than underwriting commissions)
|
| | | $ | 900,000 | | | | | $ | 900,000 | | |
Proceeds after offering expenses
|
| | | $ | 351,100,000 | | | | | $ | 403,600,000 | | |
Held in trust account(3)
|
| | | $ | 350,000,000 | | | | | $ | 402,500,000 | | |
% of public offering size
|
| | | | 100% | | | | | | 100% | | |
Not held in trust account(2)
|
| | | $ | 1,100,000 | | | | | $ | 1,100,000 | | |
| | |
Without
Over-Allotment |
| |||
Public offering price
|
| | | $ | 10.00 | | |
Net tangible book value before this offering
|
| | | | 0.0008 | | |
Increase attributable to public shareholders
|
| | | | 9.65 | | |
Decrease attributable to public shareholders
|
| | | | (10.00) | | |
Pro forma net tangible book value after this offering and the sale of the private placement shares
|
| | | $ | 0.35 | | |
Dilution to public shareholders
|
| | | $ | 9.65 | | |
| | |
Shares Purchased
|
| |
Total Consideration
|
| |
Average Price
per Share |
| |||||||||||||||||||||
| | |
Number
|
| |
Percentage
|
| |
Amount
|
| |
Percentage
|
| ||||||||||||||||||
Initial Shareholders(1)(2)
|
| | | | 11,666,667 | | | | | | 24.53% | | | | | $ | 25,000 | | | | | | 0.01% | | | | | $ | 0.002 | | |
Private Placement Shares
|
| | | | 900,000 | | | | | | 1.89% | | | | | | 9,000,000 | | | | | | 2.51% | | | | | $ | 10.000 | | |
Public Shareholders
|
| | | | 35,000,000 | | | | | | 73.58% | | | | | | 350,000,000 | | | | | | 97.49% | | | | | $ | 10.000 | | |
| | | | | 47,566,667 | | | | | | 100.00% | | | | | $ | 359,025,000 | | | | | | 100.00% | | | | | | | | |
| | |
Without
Over-Allotment |
| |||
Numerator: | | | | | | | |
Net tangible book value before this offering
|
| | | $ | 16,143 | | |
Net proceeds from this offering and sale of the private placement shares(1)
|
| | | | 351,100,000 | | |
Plus: Offering costs paid in advance, excluded from tangible book value before this offering
|
| | | | — | | |
Less: Deferred underwriting commissions
|
| | | | (12,250,000) | | |
Less: Proceeds held in trust subject to redemption(2)
|
| | | | (333,866,140) | | |
| | | | $ | 5,000,003 | | |
Denominator: | | | | | | | |
Class F ordinary shares outstanding prior to this offering
|
| | | | 20,000,000 | | |
Ordinary shares forfeited if over-allotment is not exercised
|
| | | | (16,111,111) | | |
Class G ordinary shares
|
| | | | 7,777,778 | | |
Private placement shares
|
| | | | 900,000 | | |
Class A ordinary shares offered
|
| | | | 35,000,000 | | |
Less: Ordinary shares subject to redemption
|
| | | | (33,386,614) | | |
| | | | | 14,180,053 | | |
Pro forma net tangible book value after IPO and sale of Private Placement Shares
|
| | | | 0.35 | | |
| | |
January 8, 2021
|
| |||||||||
| | |
Actual
|
| |
As Adjusted(1)
|
| ||||||
Deferred underwriting commissions
|
| | | $ | — | | | | | $ | 12,250,000 | | |
Notes payable(2)
|
| | | | — | | | | | | 300,000 | | |
Class A ordinary shares, subject to redemption(3)
|
| | | | — | | | | | | 333,866,140 | | |
Shareholders’ equity: | | | | | | | | | | | | | |
Preferred shares, $0.0001 par value, 5,000,000 shares authorized; no shares issued
or outstanding (actual and as adjusted) |
| | | | — | | | | | | — | | |
Ordinary shares, $0.0001 par value, 550,000,000 shares authorized (actual); 560,000,000 shares authorized (as adjusted)
|
| | | | | | | | | | | | |
Class A ordinary shares, 500,000,000 shares authorized (actual and as adjusted); no shares issued or outstanding (actual); 2,513,386 shares issued and outstanding (excluding 33,386,614 shares subject to redemption) (as adjusted)
|
| | | | — | | | | | | 251 | | |
Class F ordinary shares, 50,000,000 shares authorized, 20,000,000 shares issued and outstanding (actual); 30,000,000 shares authorized,3,888,889 shares issued and outstanding (as adjusted)(4)
|
| | | | 2,000 | | | | | | 389 | | |
Class G ordinary shares, no shares authorized, issued or outstanding (actual); 30,000,000 shares authorized, 7,777,778 shares issued and outstanding (as adjusted)
|
| | | | — | | | | | | 778 | | |
Additional paid-in capital(5)
|
| | | | 23,000 | | | | | | 5,007,442 | | |
Accumulated deficit
|
| | | | (8,857) | | | | | | (8,857) | | |
Total shareholders’ equity
|
| | | | 16,143 | | | | | | 5,000,003 | | |
Total capitalization
|
| | | $ | 16,143 | | | | | $ | 351,416,143 | | |
| | | |
Redemptions in
Connection with our Initial Business Combination |
| |
Other Permitted
Purchases of Public Shares by our Affiliates |
| |
Redemptions if we fail to
Complete an Initial Business Combination |
|
|
Calculation of redemption price
|
| | Redemptions at the time of our initial business combination may be made pursuant to a tender offer or in connection with a shareholder vote. The redemption price will be the same whether we conduct redemptions pursuant to a tender offer or in connection with a shareholder vote. In either case, our public shareholders may redeem their public shares for cash equal to the aggregate amount then on deposit in the trust account as of two business days prior to the consummation of the initial business combination (which is initially anticipated to be $10.00 per public share), including interest earned on the funds held in the trust account and not previously released to us to pay our taxes, divided by the number of then outstanding public shares, subject to the limitation that no redemptions will take place if all of the redemptions would cause our net tangible assets to be less than $5,000,001 and any limitations (including but not limited to cash requirements) agreed to in connection with the negotiation of terms of a proposed business combination. | | | If we seek shareholder approval of our initial business combination, our sponsor, directors, officers, advisors or their affiliates may purchase shares in privately negotiated transactions or in the open market either prior to or following completion of our initial business combination. Such purchases will only be made to the extent such purchases are able to be made in compliance with Rule 10b-18, which is a safe harbor from liability for manipulation under Section 9(a)(2) and Rule 10b-5 of the Exchange Act. None of the funds in the trust account will be used to purchase shares in such transactions. | | | If we are unable to complete our initial business combination within 24 months from the closing of this offering, we will redeem all public shares at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account (which is initially anticipated to be $10.00 per public share), including interest (less up to $100,000 of interest to pay dissolution expenses) divided by the number of then outstanding public shares. | |
|
Impact to remaining shareholders
|
| | The redemptions in connection with our initial business | | | If the permitted purchases described above are made, there | | | The redemption of our public shares if we fail to complete our initial | |
| | | |
Redemptions in
Connection with our Initial Business Combination |
| |
Other Permitted
Purchases of Public Shares by our Affiliates |
| |
Redemptions if we fail to
Complete an Initial Business Combination |
|
| | | | combination will reduce the book value per share for our remaining shareholders, who will bear the burden of the deferred underwriting commissions and interest withdrawn in order to pay our taxes (to the extent not paid from amounts accrued as interest on the funds held in the trust account). | | | will be no impact to our remaining shareholders because the purchase price would not be paid by us. | | | business combination will reduce the book value per share for the shares held by our initial shareholders, who will be our only remaining shareholders after such redemptions | |
| | | |
Terms of Our Offering
|
| |
Terms Under a Rule 419 Offering
|
|
|
Escrow of offering proceeds
|
| | The rules of the NYSE provide that at least 90% of the gross proceeds from this offering and the private placement be deposited in a U.S.-based trust account. $350,000,000 of the net proceeds of this offering and the sale of the private placement shares will be deposited into a U.S-based trust account at J.P. Morgan Chase Bank, N.A., with Continental Stock Transfer & Trust Company acting as trustee. | | | Approximately $297,675,000 of the offering proceeds, representing the gross proceeds of this offering less allowable underwriting commissions, expenses and company deductions under Rule 419, would be required to be deposited into either an escrow account with an insured depositary institution or in a separate bank account established by a broker-dealer in which the broker-dealer acts as trustee for persons having the beneficial interests in the account. | |
| | | |
Terms of Our Offering
|
| |
Terms Under a Rule 419 Offering
|
|
|
Investment of net proceeds
|
| | $350,000,000 of the net proceeds of this offering and the sale of the private placement shares held in trust will be invested only in U.S. government treasury bills with a maturity of 180 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations. Beginning in January 2022, we expect to invest the funds in the trust account in specified U.S. government treasury bills or in specified money market funds. Prior to such time, such proceeds will not be invested and will be held in a non-interest bearing trust account. Prior to such time, such proceeds will not be invested and will be held in a non-interest bearing trust account. | | | Proceeds could be invested only in specified securities such as a money market fund meeting conditions of the Investment Company Act or in securities that are direct obligations of, or obligations guaranteed as to principal or interest by, the United States. | |
|
Receipt of interest on escrowed funds
|
| | Interest income (if any) on proceeds from the trust account to be paid to shareholders is reduced by (i) any taxes paid or payable, and (ii) in the event of our liquidation for failure to complete our initial business combination within the allotted time, up to $100,000 of net interest that may be released to us should we have no or insufficient working capital to fund the costs and expenses of our dissolution and liquidation. | | | Interest income on funds in escrow account would be held for the sole benefit of investors, unless and only after the funds held in escrow were released to us in connection with our completion of a business combination. | |
|
Limitation on fair value or net assets of target business
|
| | So long as we obtain and maintain a listing for our securities on the NYSE, our initial business combination must be with one or more target businesses that together have an aggregate fair market value equal to at least 80% of the net assets in the trust account (net of amounts disbursed to management for working capital purposes and excluding the amount of any deferred underwriting discount held in trust) at the time of our signing a definitive agreement in | | | The fair value or net assets of a target business must represent at least 80% of the maximum offering proceeds. | |
| | | |
Terms of Our Offering
|
| |
Terms Under a Rule 419 Offering
|
|
| | | | connection with our initial business combination. | | | | |
|
Trading of securities issued
|
| |
The units are expected to begin trading on or promptly after the date of this prospectus. The Class A ordinary shares will begin separate trading on the 52nd day following the date of this prospectus (or if such date is not a business day, the following business day) unless the Representatives inform us of their decision to allow earlier separate trading, subject to our having filed the Current Report on Form 8-K described below and having issued a press release announcing when such separate trading will begin. We will file a Current Report on Form 8-K promptly after the closing of this offering, which is anticipated to take place three business days from the date of this prospectus. If the underwriters’ over-allotment option is exercised following the initial filing of such Current Report on Form 8-K, a second or amended Current Report on Form 8-K, which will include an audited balance sheet reflecting our receipt of the gross proceeds at the closing of this offering will be filed to provide updated financial information to reflect the exercise of the underwriters’ over-allotment option.
|
| | No trading of the Class A ordinary shares would be permitted until the completion of a business combination. During this period, the securities would be held in the escrow or trust account. | |
|
Election to remain an investor
|
| | We will provide our public shareholders with the opportunity to redeem their public shares for cash equal to their pro rata share of the aggregate amount then on deposit in the trust account as of two business days prior to the consummation of our initial business combination, including interest earned on the funds held in the trust account and not previously released to us to pay our taxes, upon the completion of our initial business combination, subject to the limitations described herein. We may not be | | | A prospectus containing information pertaining to the business combination required by the SEC would be sent to each investor. Each investor would be given the opportunity to notify the company in writing, within a period of no less than 20 business days and no more than 45 business days from the effective date of a post-effective amendment to the company’s registration statement, to decide if he, she or it elects to remain a shareholder of the company or require the return of his, her or its investment. If the company | |
| | | |
Terms of Our Offering
|
| |
Terms Under a Rule 419 Offering
|
|
| | | | required by law to hold a shareholder vote. If we are not required by law and do not otherwise decide to hold a shareholder vote, we will, pursuant to our amended and restated memorandum and articles of association, conduct the redemptions pursuant to the tender offer rules of the SEC and file tender offer documents with the SEC which will contain substantially the same financial and other information about the initial business combination and the redemption rights as is required under the SEC’s proxy rules. | | | has not received the notification by the end of the 45th business day, funds and interest or dividends, if any, held in the trust or escrow account are automatically returned to the shareholder. Unless a sufficient number of investors elect to remain investors, all funds on deposit in the escrow account must be returned to all of the investors and none of the securities are issued. | |
| | | | If, however, we hold a shareholder vote, we will, like many blank check companies, offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If we seek shareholder approval, we will complete our initial business combination only if we obtain the approval of an ordinary resolution under Cayman Islands law, being the affirmative vote of a majority of the ordinary shares represented in person or by proxy and entitled to vote thereon and who vote at a general meeting. Additionally, each public shareholder may elect to redeem its public shares irrespective of whether they vote for or against the proposed transaction. Our amended and restated memorandum and articles of association require that at least five days’ notice will be given of any such general meeting. | | | | |
|
Business combination deadline
|
| | If we are unable to complete an initial business combination within 24 months from the closing of this offering, we will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible | | | If an acquisition has not been completed within 18 months after the effective date of the company’s registration statement, funds held in the trust or escrow account are returned to investors. | |
| | | |
Terms of Our Offering
|
| |
Terms Under a Rule 419 Offering
|
|
| | | | but not more than ten business days thereafter, redeem 100% of the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account and not previously released to us to pay our taxes (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining shareholders and our board of directors, dissolve and liquidate, subject in each case to our obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. | | | | |
|
Release of funds
|
| | Except with respect to interest earned on the funds held in the trust account that may be released to us to pay our taxes, if any, the proceeds from this offering and the sale of the private placement shares held in the trust account will not be released from the trust account until the earliest of (a) the completion of our initial business combination, (b) the redemption of any public shares properly submitted in connection with a shareholder vote to amend our amended and restated memorandum and articles of association (i) to modify the substance or timing of our obligation to redeem 100% of our public shares if we do not complete our initial business combination within 24 months | | | The proceeds held in the escrow account are not released until the earlier of the completion of a business combination or the failure to effect a business combination within the allotted time. | |
| | | |
Terms of Our Offering
|
| |
Terms Under a Rule 419 Offering
|
|
| | | | from the closing of this offering or (ii) with respect to any other provisions relating to shareholders’ rights or pre-initial business combination activity; and (c) the redemption of all of our public shares if we are unable to complete our initial business combination within 24 months from the closing of this offering, subject to applicable law. The Company will instruct the Trustee to pay amounts from the trust account directly to redeeming holders. | | | | |
Name
|
| |
Age
|
| |
Title
|
| |||
Karl Peterson
|
| | | | 50 | | | | Non-Executive Chairman and Director | |
Anilu Vazquez-Ubarri
|
| | | | 44 | | | | Director | |
Mark Fields
|
| | | | 60 | | | | Director nominee | |
Maryanne Hancock
|
| | | | 46 | | | | Director nominee | |
Chad Leat
|
| | | | 65 | | | | Director nominee | |
Nancy Mahon
|
| | | | 56 | | | | Director nominee | |
Kneeland Youngblood
|
| | | | 65 | | | | Director nominee | |
Michael MacDougall
|
| | | | 50 | | | | President | |
Martin Davidson
|
| | | | 44 | | | | Chief Financial Officer | |
Eduardo Tamraz
|
| | | | 37 | | | |
Executive Vice President of Corporate Development, Secretary
|
|
Individual
|
| |
Entity
|
| |
Entity’s Business
|
| |
Affiliation
|
|
Karl Peterson | | | Accel Entertainment, Inc. | | | Gaming | | | Director | |
| | | Playa Hotels and Resorts, B.V | | | Resorts | | | Chairman and Director | |
| | | Sabre Corporation and related entities | | | Technology | | | Director | |
| | | TPG Global, LLC (and affiliated entities) | | | Alternative Investment Manager | | | Partner | |
| | | TPG Pace Beneficial Finance Corp. | | | Investment | | | Non-Executive Chairman and Director | |
| | | TPG Pace Tech Opportunities Corp. | | | Investment | | | Non-Executive Chairman and Director | |
| | | TPG Pace Tech Opportunities II Corp. | | | Investment | | | Non-Executive Chairman and Director | |
| | | TPG Pace Solutions Corp. | | | Investment | | | Non-Executive Chairman and Director | |
Anilu Vazquez-Ubarri | | | Upwork | | | Human Resources | | | Director | |
| | | TPG Global, LLC (and affiliated entities) | | | Alternative Investment Manager | | | Partner and Chief Human Resources Officer | |
Mark Fields | | | Qualcomm | | | Technology | | | Director | |
| | | Tanium | | | Technology | | | Lead Director | |
| | | TPG Global, LLC (and affiliated entities) | | | Alternative Investment Manager | | | Senior Advisor | |
| | | TPG Pace Solutions Corp. | | | Investment | | | Director(1) | |
Maryanne Hancock | | | Y Analytics | | | Consulting | | | Chief Executive Officer | |
| | | TPG Pace Beneficial Finance Corp. | | | Investment | | | Director | |
Chad Leat | | | J. Crew Group Inc. | | | Retail | | | Director | |
| | | Midcap Financial | | | Commercial Lending | | | Director | |
| | | Norwegian Cruise Line Holdings Ltd. | | | Travel | | | Director | |
| | | TPG Pace Benefical Finance Corp. | | | Investment | | | Director | |
| | | TPG Pace Tech Opportunities Corp. | | | Investment | | | Director | |
| | | TPG Pace Tech Opportunities II Corp. | | | Investment | | | Director(2) | |
Individual
|
| |
Entity
|
| |
Entity’s Business
|
| |
Affiliation
|
|
Nancy Mahon | | |
Estée Lauder Companies
|
| | Cosmetics | | | Senior Vice President for Global Corporate Citizenship and Sustainability | |
| | | TPG Pace Beneficial Finance Corp. | | | Investment | | | Director | |
Kneeland Youngblood | | | Mallinckrodt Pharmaceuticals | | | Pharmaceuticals | | | Director | |
| | | Pharos Capital Group, LLC | | | Alternative Investment Manager | | | Officer | |
| | | Scientific Games Corporation | | | Computer | | | Director | |
| | | TPG Pace Beneficial Finance Corp. | | | Investment | | | Director | |
| | | TPG Pace Tech Opportunities Corp. | | | Investment | | | Director | |
| | | TPG Pace Solutions Corp. | | | Investment | | | Director(3) | |
Michael MacDougall | | | TPG Global, LLC (and affiliated entities) | | | Alternative Investment Manager | | | Partner | |
| | | TPG Pace Beneficial Finance Corp. | | | Investment | | | President | |
Martin Davidson | | | TPG Global, LLC (and affiliated entities) | | | Alternative Investment Manager | | | Partner and Chief Accounting Officer | |
| | | TPG Pace Beneficial Finance Corp. | | | Investment | | | Chief Financial Officer | |
| | | TPG Pace Tech Opportunities Corp. | | | Investment | | | Chief Financial Officer | |
| | | TPG Pace Tech Opportunities II Corp. | | | Investment | | |
Chief Financial Officer(4)
|
|
| | | TPG Pace Solutions Corp. | | | Investment | | |
Chief Financial Officer(4)
|
|
Eduardo Tamraz | | | TPG Global, LLC (and affiliated entities) | | | Alternative Investment Manager | | | Principal | |
| | | TPG Pace Beneficial Finance Corp. | | | Investment | | | Secretary | |
| | | TPG Pace Tech Opportunities Corp. | | | Investment | | | Executive Vice President of Corporate Development and Secretary | |
| | | TPG Pace Tech Opportunities II Corp. | | | Investment | | | Executive Vice President of Corporate Development and Secretary(5) | |
| | | TPG Pace Solutions Corp. | | | Investment | | | President(5) | |
| | |
Number of
Shares Beneficially Owned(2)(3) |
| |
Approximate
Percentage of Outstanding Ordinary Shares |
| ||||||||||||
Name and Address of Beneficial Owner(1)
|
| |
Before
Offering |
| |
After
Offering(2) |
| ||||||||||||
TPG Pace Beneficial II Sponsor, Series LLC(4)
|
| | | | 3,728,889 | | | | | | 95.9% | | | | | | % | | |
Karl Peterson(4)
|
| | | | 3,728,889 | | | | | | 95.9% | | | | | | % | | |
Anilu Vazquez-Ubarri
|
| | | | — | | | | | | * | | | | | | * | | |
Mark Fields
|
| | | | 40,000 | | | | | | 1.0% | | | | | | * | | |
Maryanne Hancock
|
| | | | — | | | | | | * | | | | | | * | | |
Chad Leat
|
| | | | 40,000 | | | | | | 1.0% | | | | | | * | | |
Nancy Mahon
|
| | | | 40,000 | | | | | | 1.0% | | | | | | * | | |
Kneeland Youngblood
|
| | | | 40,000 | | | | | | 1.0% | | | | | | * | | |
Michael MacDougall
|
| | | | — | | | | | | * | | | | | | * | | |
Martin Davidson
|
| | | | — | | | | | | * | | | | | | * | | |
Eduardo Tamraz
|
| | | | — | | | | | | * | | | | | | * | | |
All directors, officers and director nominees as a group (10 individuals)
|
| | | | 160,000 | | | | | | 100% | | | | | | % | | |
Underwriter
|
| |
Number of
Shares |
|
Deutsche Bank Securities Inc.
|
| | | |
J.P. Morgan Securities LLC
|
| | | |
Goldman Sachs & Co. LLC
|
| | | |
Northland Securities, Inc.
|
| | | |
Siebert Williams Shank & Co., LLC
|
| | | |
Total
|
| | |
| | |
Paid by TPG Pace
Beneficial II Corp. |
| |||||||||
| | |
No Exercise
|
| |
Full Exercise
|
| ||||||
Per Share(1)
|
| | | $ | 0.55 | | | | | $ | 0.55 | | |
Total(1) | | | | $ | 19,250,000 | | | | | $ | 22,137,500 | | |
| | | | | F-2 | | | |
| Financial Statements: | | | | | | | |
| | | | | F-3 | | | |
| | | | | F-4 | | | |
| | | | | F-5 | | | |
| | | | | F-6 | | | |
| | | | | F-7 | | |
| | |
January 8, 2021
|
| |||
Assets | | | | | | | |
Current assets: | | | | | | | |
Cash
|
| | | $ | 25,000 | | |
Deferred offering costs
|
| | | | 31,952 | | |
Total assets
|
| | | $ | 56,952 | | |
Liabilities and shareholder’s equity | | | | | | | |
Current liabilities: | | | | | | | |
Accrued formation and offering costs
|
| | | $ | 40,809 | | |
Total liabilities
|
| | | | 40,809 | | |
Commitments and contingencies | | | | | | | |
Shareholder’s equity: | | | | | | | |
Preferred shares, $0.0001 par value; 5,000,000 shares authorized, none issued or
outstanding |
| | | | — | | |
Class A ordinary shares, $0.0001 par value; 500,000,000 shares authorized, none issued or
outstanding |
| | | | — | | |
Class F ordinary shares, $0.0001 par value; 50,000,000 shares authorized, 20,000,000 shares issued and outstanding
|
| | | | 2,000 | | |
Additional paid-in capital
|
| | | | 23,000 | | |
Accumulated deficit
|
| | | | (8,857) | | |
Total shareholder’s equity
|
| | | | 16,143 | | |
Total liabilities and shareholder’s equity
|
| | | $ | 56,952 | | |
| | |
For the Period
from January 4, 2021 (inception) to January 8, 2021 |
| |||
Revenue
|
| | | $ | — | | |
Formation costs
|
| | | | 8,857 | | |
Net loss attributable to ordinary shares
|
| | | $ | (8,857) | | |
Net loss per ordinary share: | | | | | | | |
Basic and diluted
|
| | | $ | (0.00) | | |
Weighted average ordinary shares outstanding: | | | | | | | |
Basic and diluted
|
| | | | 4,000,000 | | |
| | |
Preferred
Shares |
| |
Class A
Ordinary Shares |
| |
Class F
Ordinary Shares |
| |
Additional
Paid-In Capital |
| |
Accumulated
Deficit |
| |
Shareholder’s
Equity |
| ||||||||||||||||||||||||||||||||||||
| | |
Shares
|
| |
Amount
|
| |
Shares
|
| |
Amount
|
| |
Shares
|
| |
Amount
|
| ||||||||||||||||||||||||||||||||||||
Balance at January 4, 2021 (inception)
|
| | | | — | | | | | $ | — | | | | | | — | | | | | $ | — | | | | | | — | | | | | $ | — | | | | | $ | — | | | | | $ | — | | | | | $ | — | | |
Sale of Class F ordinary shares to Sponsor on January 8, 2021 at $0.001 per share
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 20,000,000 | | | | | | 2,000 | | | | | | 23,000 | | | | | | — | | | | | | 25,000 | | |
Net loss attributable to ordinary shares
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (8,857) | | | | | | (8,857) | | |
Balance at January 8, 2021
|
| | | | — | | | | | $ | — | | | | | | — | | | | | $ | — | | | | | | 20,000,000 | | | | | $ | 2,000 | | | | | $ | 23,000 | | | | | $ | (8,857) | | | | | $ | 16,143 | | |
| | |
For the Period
from January 4, 2021 (inception) to January 8, 2021 |
| |||
Cash flows from operating activities: | | | | | | | |
Net loss attributable to ordinary shares
|
| | | $ | (8,857) | | |
Changes in operating assets and liabilities:
|
| | | | | | |
Deferred offering costs
|
| | | | (31,952) | | |
Accrued formation and offering costs
|
| | | | 40,809 | | |
Net cash provided by operating activities
|
| | | | — | | |
Cash flows from financing activities: | | | | | | | |
Proceeds from sale of Class F ordinary shares to Sponsor
|
| | | | 25,000 | | |
Net cash provided by financing activities
|
| | | | 25,000 | | |
Net change in cash
|
| | | | 25,000 | | |
Cash at beginning of period
|
| | | | — | | |
Cash at end of period
|
| | | $ | 25,000 | | |
|
Legal fees and expenses
|
| | | $ | 250,000 | | |
|
Accounting fees and expenses
|
| | | | 90,250 | | |
|
SEC expenses
|
| | | | 43,913 | | |
|
FINRA expenses
|
| | | | 43,625 | | |
|
Travel and road show
|
| | | | 5,000 | | |
|
Directors and officers insurance(1)
|
| | | | 250,000 | | |
|
NYSE listing and filing fees
|
| | | | 85,000 | | |
|
Miscellaneous expenses
|
| | | | 132,212 | | |
|
Total offering expenses
|
| | | $ | 900,000 | | |
|
Exhibit
No. |
| |
Description
|
|
| 1.1 | | | Form of Underwriting Agreement. | |
| 3.1 | | | Certificate of Incorporation. | |
| 3.2 | | | Amended and Restated Memorandum and Articles of Association. | |
| 3.3 | | | Form of Amended and Restated Memorandum and Articles of Association. | |
| 4.2 | | | Specimen Class A Ordinary Share Certificate. | |
| 5.1 | | | Opinion of Weil, Gotshal & Manges LLP, Legal Counsel to the Registrant. | |
| 5.2 | | | Opinion of Maples and Calder, Cayman Islands, Legal Counsel to the Registrant. | |
| 10.1 | | | Promissory Note, dated , 2021, issued to TPG Pace Beneficial II Sponsor, Series LLC. | |
| 10.2 | | | Form of Letter Agreement among the Registrant and its officers and directors and TPG Pace Beneficial II Sponsor, Series LLC. | |
| 10.3 | | | Form of Investment Management Trust Agreement between Continental Stock Transfer & Trust Company and the Registrant. | |
| 10.4 | | | Form of Registration Rights Agreement among the Registrant and certain security holders. | |
| 10.5 | | | Securities Subscription Agreement, dated January 12, 2021, between the Registrant and TPG Pace Beneficial II Sponsor, Series LLC.* | |
| 10.6 | | | Form of Private Placement Shares Purchase Agreement between the Registrant and TPG Pace Beneficial II Sponsor, Series LLC. | |
| 10.7 | | | Form of Indemnity Agreement. | |
| 10.8 | | | Form of Administrative Services Agreement between the Registrant and TPG Pace Beneficial II Sponsor, Series LLC. | |
| 10.9 | | | Form of Forward Purchase Agreement between the Registrant and an affiliate of TPG Global, LLC. | |
| 10.10 | | | Form of Forward Purchase Agreement between the Registrant and other third parties. | |
| 10.11 | | | Form of Engagement Letter between the Registrant and TPG Capital BD, LLC. | |
| 23.1 | | | Consent of KPMG LLP.* | |
| 23.2 | | | Consent of Weil, Gotshal & Manges LLP (included on Exhibit 5.1). | |
| 23.3 | | | Consent of Maples and Calder (included on Exhibit 5.2). | |
| 24.1 | | | Power of Attorney (included on signature page of this Registration Statement). | |
| 99.1 | | | Consent of Anilu Vazquez-Ubarri.* | |
| 99.2 | | | Consent of Mark Fields.* | |
| 99.3 | | | Consent of Maryanne Hancock.* | |
| 99.4 | | | Consent of Chad Leat.* | |
| 99.5 | | | Consent of Nancy Mahon.* | |
| 99.6 | | | |
|
Name
|
| |
Position
|
| |
Date
|
|
|
/s/ Michael MacDougall
Michael MacDougall
|
| |
President (Principal Executive Officer)
|
| |
March 8, 2021
|
|
|
/s/ Martin Davidson
Martin Davidson
|
| |
Chief Financial Officer (PrincipalFinancial and Accounting Officer)
|
| |
March 8, 2021
|
|
|
/s/ Karl Peterson
Karl Peterson
|
| |
Non-Executive Chairman and Director
|
| |
March 8, 2021
|
|
Exhibit 10.5
TPG Pace VII Holdings Corp.
c/o TPG Global, LLC
301 Commerce St., Suite 3300
Fort Worth, TX 76102
TPG Pace VII Sponsor (Series S) 301 Commerce St., Suite 3300 Fort Worth, TX 76102 |
January 12, 2021 |
RE: Securities Subscription Agreement
Ladies and Gentlemen:
This agreement and the terms hereof (this “Agreement”) memorializes the purchase of 20,000,000 of Class B ordinary shares (the “Shares”), $0.0001 par value per share (the “Class B Shares”) in TPG Pace VII Holdings Corp., a Cayman Islands exempted company (the “Company”) by TPG Pace VII Sponsor (Series S), a series of TPG Pace VII Sponsor, Series LLC, a Delaware series limited liability company (the “Subscriber” or “you”), which occurred on January 8, 2021 (the “Effective Date”). For the purposes of this Agreement, references to “Ordinary Shares” are to, collectively, the Class B Shares and the Company’s Class A ordinary shares, $0.0001 par value per share (the “Class A Shares”). Pursuant to the Company’s memorandum and articles of association, as amended to the date hereof (the “Articles”), Class B Shares will convert into Class A Shares on a one-for-one basis, subject to adjustment, upon the terms and conditions set forth in the Articles. Unless the context otherwise requires, as used herein “Shares” shall be deemed to include any Class A Shares issued upon conversion of the Class B Shares comprising the Shares. The terms on which the Company sold the Shares to the Subscriber on the Effective Date, and the Company and the Subscriber’s agreements regarding such Shares, are as follows:
1. | Purchase of Shares. |
With effect as of the Effective Date, for the sum of $25,000 (the “Purchase Price”), which the Company acknowledges receiving in cash, the Company sold and issued the Shares to the Subscriber, and the Subscriber purchased the Shares from the Company, on the terms and subject to the conditions set forth in this Agreement. Concurrently with the Subscriber’s execution of this Agreement, the Company shall, at its option, deliver to the Subscriber a certificate registered in the Subscriber’s name representing the Shares (the “Original Certificate”) or effect such delivery in book-entry form. Any future forfeiture of shares of the Company (as agreed between the Subscriber and the Company) shall take effect as surrenders for no consideration of such shares as a matter of Cayman Islands law.
2. | Representations, Warranties and Agreements. |
2.1 Subscriber’s Representations, Warranties and Agreements. To induce the Company to issue the Shares to the Subscriber, the Subscriber hereby represents and warrants to the Company and agrees with the Company as follows (such representations being true as of the Effective Date or the date hereof, as applicable):
2.1.1 No Government Recommendation or Approval. The Subscriber understands that no federal or state agency has passed upon or made any recommendation or endorsement of the offering of the Shares.
2.1.2 No Conflicts. The execution, delivery and performance of this Agreement and the consummation by the Subscriber of the transactions contemplated hereby do not violate, conflict with or constitute a default under (i) the formation and governing documents of the Subscriber, (ii) any agreement, indenture or instrument to which the Subscriber is a party or (iii) any law, statute, rule or regulation to which the Subscriber is subject, or any agreement, order, judgment or decree to which the Subscriber is subject.
2.1.3 Organization and Authority. The Subscriber is a Delaware limited liability company, validly existing and in good standing under the laws of the State of Delaware and possesses all requisite power and authority necessary to carry out the transactions contemplated by this Agreement. Upon execution and delivery by you, this Agreement is a legal, valid and binding agreement of Subscriber, enforceable against Subscriber in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, fraudulent conveyance or similar laws affecting the enforcement of creditors’ rights generally and subject to general principles of equity (regardless of whether enforcement is sought in a proceeding at law or in equity).
2.1.4 Experience, Financial Capability and Suitability. Subscriber is: (i) sophisticated in financial matters and is able to evaluate the risks and benefits of the investment in the Shares and (ii) able to bear the economic risk of its investment in the Shares for an indefinite period of time because the Shares have not been registered under the Securities Act (as defined below) and therefore cannot be sold unless subsequently registered under the Securities Act or an exemption from such registration is available. Subscriber is capable of evaluating the merits and risks of its investment in the Company and has the capacity to protect its own interests. Subscriber must bear the economic risk of this investment until the Shares are sold pursuant to: (i) an effective registration statement under the Securities Act or (ii) an exemption from registration available with respect to such sale. Subscriber is able to bear the economic risks of an investment in the Shares and to afford a complete loss of Subscriber’s investment in the Shares.
2.1.5 Access to Information; Independent Investigation. Prior to the execution of this Agreement, the Subscriber has had the opportunity to ask questions of and receive answers from representatives of the Company concerning an investment in the Company, as well as the finances, operations, business and prospects of the Company, and the opportunity to obtain additional information to verify the accuracy of all information so obtained. In determining whether to make this investment, Subscriber has relied solely on Subscriber’s own knowledge and understanding of the Company and its business based upon Subscriber’s own due diligence investigation and the information furnished pursuant to this paragraph. Subscriber understands that no person has been authorized to give any information or to make any representations which were not furnished pursuant to this Section 2 and Subscriber has not relied on any other representations or information in making its investment decision, whether written or oral, relating to the Company, its operations and/or its prospects.
2.1.6 Regulation D Offering. Subscriber represents that it is an “accredited investor” as such term is defined in Rule 501(a) of Regulation D under the Securities Act of 1933, as amended (the “Securities Act”) and acknowledges the sale contemplated hereby is being made in reliance on a private placement exemption to “accredited investors” within the meaning of Section 501(a) of Regulation D under the Securities Act or similar exemptions under state law.
2.1.7 Investment Purposes. The Subscriber is purchasing the Shares solely for investment purposes, for the Subscriber’s own account and not for the account or benefit of any other person, and not with a view towards the distribution or dissemination thereof. The Subscriber did not decide to enter into this Agreement as a result of any general solicitation or general advertising within the meaning of Rule 502 under the Securities Act.
2.1.8 Restrictions on Transfer; Shell Company. Subscriber understands the Shares are being offered in a transaction not involving a public offering within the meaning of the Securities Act. Subscriber understands the Shares will be “restricted securities” within the meaning of Rule 144(a)(3) under the Securities Act and Subscriber understands that the certificates or book-entries representing the Shares will contain a legend in respect of such restrictions. If in the future the Subscriber decides to offer, resell, pledge or otherwise transfer the Shares, such Shares may be offered, resold, pledged or otherwise transferred only pursuant to: (i) registration under the Securities Act, or (ii) an available exemption from registration. Subscriber agrees that if any transfer of its Shares or any interest therein is proposed to be made, as a condition precedent to any such transfer, Subscriber may be required to deliver to the Company an opinion of counsel satisfactory to the Company. Absent registration or an exemption, the Subscriber agrees not to resell the Shares. Subscriber further acknowledges that because the Company is a shell company, Rule 144 may not be available to the Subscriber for the resale of the Shares until one year following consummation of the initial business combination of the Company, despite technical compliance with the requirements of Rule 144 and the release or waiver of any contractual transfer restrictions.
2.1.9 No Governmental Consents. No governmental, administrative or other third party consents or approvals are required, necessary or appropriate on the part of Subscriber in connection with the transactions contemplated by this Agreement.
2.2 Company’s Representations, Warranties and Agreements. To induce the Subscriber to purchase the Shares, the Company hereby represents and warrants to the Subscriber and agrees with the Subscriber as follows:
2.2.1 Organization and Corporate Power. The Company is a Cayman Islands exempted company and is qualified to do business in every jurisdiction in which the failure to so qualify would reasonably be expected to have a material adverse effect on the financial condition, operating results or assets of the Company. The Company possesses all requisite corporate power and authority necessary to carry out the transactions contemplated by this Agreement.
2.2.2 No Conflicts. The execution, delivery and performance of this Agreement and the consummation by the Company of the transactions contemplated hereby do not violate, conflict with or constitute a default under (i) the Memorandum and Articles of Association of the Company, (ii) any agreement, indenture or instrument to which the Company is a party or (iii) any law, statute, rule or regulation to which the Company is subject, or any agreement, order, judgment or decree to which the Company is subject.
2.2.3 Title to Shares. Upon issuance in accordance with, and payment pursuant to, the terms hereof, and registration on the register of members of the Company, the Shares will be duly and validly issued, fully paid and nonassessable. Upon issuance in accordance with, and payment pursuant to, the terms hereof the Subscriber will have or receive good title to the Shares, free and clear of all liens, claims and encumbrances of any kind, other than (a) transfer restrictions hereunder and under the other agreements to which the Shares may be subject, (b) transfer restrictions under federal and state securities laws, and (c) liens, claims or encumbrances imposed due to the actions of the Subscriber.
2.2.4 No Adverse Actions. There are no actions, suits, investigations or proceedings pending, threatened against or affecting the Company which: (i) seek to restrain, enjoin, prevent the consummation of or otherwise affect the transactions contemplated by this Agreement or (ii) question the validity or legality of any transactions or seeks to recover damages or to obtain other relief in connection with any transactions.
2.2.5 Authorization. The Class A Shares issuable upon conversion of the Class B Shares have been duly authorized and reserved for issuance upon such conversion.
2.3 Termination of Rights as Shareholder. If any of the Shares are forfeited, then after such time the Subscriber (or successor in interest), shall no longer have any rights as a holder of such forfeited Shares, and the Company shall take such action as is appropriate to cancel such forfeited Shares.
2.4 Share Certificates. In the event an adjustment to the Original Certificate, if any, is required pursuant to this Section 3, then the Subscriber shall return such Original Certificate to the Company or its designated agent as soon as practicable upon its receipt of notice from the Company advising Subscriber of such adjustment, following which a new certificate (the “New Certificate”), if any, shall be issued in such amount representing the adjusted number of Shares held by the Subscriber. The New Certificate, if any, shall be returned to the Subscriber as soon as practicable. Any such adjustment for any uncertificated securities held by the Subscriber shall be made in book-entry form.
3. Waiver of Liquidation Distributions; Redemption Rights. In connection with the Shares purchased pursuant to this Agreement, the Subscriber hereby waives any and all right, title, interest or claim of any kind in or to any distributions by the Company from the trust account which will be established for the benefit of the Company’s public shareholders and into which substantially all of the proceeds of the IPO will be deposited (the “Trust Account”), in the event of a liquidation of the Company upon the Company’s failure to timely complete an initial business combination. For purposes of clarity, in the event the Subscriber purchases securities in the IPO or in the aftermarket, any Class A Shares so purchased shall be eligible to receive any liquidating distributions by the Company. However, in no event will the Subscriber have the right to redeem any Ordinary Shares held by it into funds held in the Trust Account upon the successful completion of an initial business combination.
4. | Restrictions on Transfer. |
4.1 Securities Law Restrictions. In addition to any restrictions to be contained in that certain letter agreement (commonly known as an “Insider Letter”) to be dated on or prior to the closing of the IPO by and between Subscriber and the Company, Subscriber agrees not to sell, transfer, pledge, hypothecate or otherwise dispose of all or any part of the Shares unless, prior thereto (a) a registration statement on the appropriate form under the Securities Act and applicable state securities laws with respect to the Shares proposed to be transferred shall then be effective or (b) the Company has received an opinion from counsel reasonably satisfactory to the Company, that such registration is not required because such transaction is exempt from registration under the Securities Act and the rules promulgated by the Securities and Exchange Commission thereunder and with all applicable state securities laws.
4.2 Restrictive Legends. All certificates representing the Shares shall have endorsed thereon legends substantially as follows:
“THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS AND NEITHER THE SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT OR SUCH LAWS OR AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT AND SUCH LAWS WHICH, IN THE OPINION OF COUNSEL, IS AVAILABLE.”
“THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A LOCKUP AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED DURING THE TERM OF THE LOCKUP.”
4.3 Additional Shares or Substituted Securities. In the event of the declaration of a share dividend, the declaration of an extraordinary dividend payable in a form other than shares, a spin-off, a share split, an adjustment in conversion ratio, a recapitalization or a similar transaction affecting the Company’s outstanding Ordinary Shares without receipt of consideration, any new, substituted or additional securities or other property which are by reason of such transaction distributed with respect to any Shares subject to this Section 5 or into which such Shares thereby become convertible shall immediately be subject to this Section 5 and Section 3. Appropriate adjustments to reflect the distribution of such securities or property shall be made to the number and/or class of Shares subject to this Section 5 and Section 3.
4.4 Registration Rights. Subscriber acknowledges that the Shares are being purchased pursuant to an exemption from the registration requirements of the Securities Act and will become freely tradable only after certain conditions are met or they are registered pursuant to a registration rights agreement to be entered into with the Company prior to the closing of the IPO (the “Registration Rights Agreement”).
5. | Other Agreements. |
5.1 Further Assurances. Subscriber agrees to execute such further instruments and to take such further action as may reasonably be necessary to carry out the intent of this Agreement.
5.2 Notices. All notices, statements or other documents which are required or contemplated by this Agreement shall be: (i) in writing and delivered personally or sent by first class registered or certified mail, overnight courier service or facsimile or electronic transmission to the address designated in writing, (ii) by facsimile to the number most recently provided to such party or such other address or fax number as may be designated in writing by such party and (iii) by electronic mail, to the electronic mail address most recently provided to such party or such other electronic mail address as may be designated in writing by such party. Any notice or other communication so transmitted shall be deemed to have been given on the day of delivery, if delivered personally, on the business day following receipt of written confirmation, if sent by facsimile or electronic transmission, one (1) business day after delivery to an overnight courier service or five (5) days after mailing if sent by mail.
5.3 Entire Agreement. This Agreement, the Insider Letter and the Registration Rights Agreement each, substantially in the form to be filed as an exhibit to the Registration Statement, embodies the entire agreement and understanding between the Subscriber and the Company with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof. No statement, representation, warranty, covenant or agreement of any kind not expressly set forth in this Agreement shall affect, or be used to interpret, change or restrict, the express terms and provisions of this Agreement.
5.4 Modifications and Amendments. The terms and provisions of this Agreement may be modified or amended only by written agreement executed by all parties hereto.
5.5 Waivers and Consents. The terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only by written document executed by the party entitled to the benefits of such terms or provisions. No such waiver or consent shall be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether or not similar. Each such waiver or consent shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver or consent.
5.6 Assignment. The rights and obligations under this Agreement may not be assigned by either party hereto without the prior written consent of the other party.
5.7 Benefit. All statements, representations, warranties, covenants and agreements in this Agreement shall be binding on the parties hereto and shall inure to the benefit of the respective successors and permitted assigns of each party hereto. Nothing in this Agreement shall be construed to create any rights or obligations except among the parties hereto, and no person or entity shall be regarded as a third-party beneficiary of this Agreement.
5.8 Governing Law. This Agreement and the rights and obligations of the parties hereunder shall be construed in accordance with and governed by the laws of New York applicable to contracts wholly performed within the borders of such state, without giving effect to the conflict of law principles thereof.
5.9 Severability. In the event that any court of competent jurisdiction shall determine that any provision, or any portion thereof, contained in this Agreement shall be unreasonable or unenforceable in any respect, then such provision shall be deemed limited to the extent that such court deems it reasonable and enforceable, and as so limited shall remain in full force and effect. In the event that such court shall deem any such provision, or portion thereof, wholly unenforceable, the remaining provisions of this Agreement shall nevertheless remain in full force and effect
5.10 No Waiver of Rights, Powers and Remedies. No failure or delay by a party hereto in exercising any right, power or remedy under this Agreement, and no course of dealing between the parties hereto, shall operate as a waiver of any such right, power or remedy of such party. No single or partial exercise of any right, power or remedy under this Agreement by a party hereto, nor any abandonment or discontinuance of steps to enforce any such right, power or remedy, shall preclude such party from any other or further exercise thereof or the exercise of any other right, power or remedy hereunder. The election of any remedy by a party hereto shall not constitute a waiver of the right of such party to pursue other available remedies. No notice to or demand on a party not expressly required under this Agreement shall entitle the party receiving such notice or demand to any other or further notice or demand in similar or other circumstances or constitute a waiver of the rights of the party giving such notice or demand to any other or further action in any circumstances without such notice or demand.
5.11 Survival of Representations and Warranties. All representations and warranties made by the parties hereto in this Agreement or in any other agreement, certificate or instrument provided for or contemplated hereby, shall survive the execution and delivery hereof and any investigations made by or on behalf of the parties.
5.12 No Broker or Finder. Each of the parties hereto represents and warrants to the other that no broker, finder or other financial consultant has acted on its behalf in connection with this Agreement or the transactions contemplated hereby in such a way as to create any liability on the other. Each of the parties hereto agrees to indemnify and save the other harmless from any claim or demand for commission or other compensation by any broker, finder, financial consultant or similar agent claiming to have been employed by or on behalf of such party and to bear the cost of legal expenses incurred in defending against any such claim.
5.13 Headings and Captions. The headings and captions of the various subdivisions of this Agreement are for convenience of reference only and shall in no way modify or affect the meaning or construction of any of the terms or provisions hereof.
5.14 Counterparts. This Agreement may be executed in one or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or any other form of electronic delivery, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such signature page were an original thereof.
5.15 Construction. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. If an ambiguity or question of intent or interpretation arises, this Agreement will be construed as if drafted jointly by the parties hereto and no presumption or burden of proof will arise favoring or disfavoring any party hereto because of the authorship of any provision of this Agreement. The words “include,” “includes,” and “including” will be deemed to be followed by “without limitation.” Pronouns in masculine, feminine, and neuter genders will be construed to include any other gender, and words in the singular form will be construed to include the plural and vice versa, unless the context otherwise requires. The words “this Agreement,” “herein,” “hereof,” “hereby,” “hereunder,” and words of similar import refer to this Agreement as a whole and not to any particular subdivision unless expressly so limited. The parties hereto intend that each representation, warranty, and covenant contained herein will have independent significance. If any party hereto has breached any representation, warranty, or covenant contained herein in any respect, the fact that there exists another representation, warranty or covenant relating to the same subject matter (regardless of the relative levels of specificity) which such party hereto has not breached will not detract from or mitigate the fact that such party hereto is in breach of the first representation, warranty, or covenant.
5.16 Mutual Drafting. This Agreement is the joint product of the Subscriber and the Company and each provision hereof has been subject to the mutual consultation, negotiation and agreement of such parties and shall not be construed for or against any party hereto.
6. Voting and Tender of Shares. Subscriber agrees to vote the Shares in favor of an initial business combination that the Company negotiates and submits for approval to the Company’s shareholders and shall not seek redemption with respect to such Shares. Additionally, the Subscriber agrees not to tender any Shares in connection with a tender offer presented to the Company’s shareholders in connection with an initial business combination negotiated by the Company.
7. Indemnification. Each party shall indemnify the other against any loss, cost or damages (including reasonable attorney’s fees and expenses) incurred as a result of such party’s breach of any representation, warranty, covenant or agreement in this Agreement.
If the foregoing accurately sets forth our understanding and agreement, please sign the enclosed copy of the Agreement and return it to us.
Very truly yours, | ||
TPG PACE VII HOLDINGS CORP. | ||
By: | /s/ Michael LaGatta | |
Name: | Michael LaGatta | |
Title: | Vice President | |
Accepted and agreed this 12th day of January, 2021 | ||
TPG Pace VII Sponsor (Series S) | ||
By its Managing Member | ||
TPG Pace Governance, LLC |
By: | /s/ Ken Murphy | |
Name: | Ken Murphy | |
Title: | Vice President |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
TPG Pace Beneficial II Corp.:
We consent to the use of our report dated January 15, 2021, except as to Notes 1, 3, 4 and 6, which are as of March 8, 2021, with respect to the balance sheet of TPG Pace Beneficial II Corp. as of January 8, 2021, the related statements of operations, changes in shareholder’s equity, and cash flows for the period from January 4, 2021 (inception) through January 8, 2021, and the related notes, included herein, and to the reference to our firm under the heading “Experts” in the prospectus.
/s/ KPMG LLP
Fort Worth, Texas
March 8, 2021
Exhibit 99.1
Consent to be Named as a Director Nominee
In connection with the filing by TPG Pace Beneficial II Corp. of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of TPG Pace Beneficial II Corp. in the Registration Statement and any and all amendments and supplements thereto. I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.
Dated: March 8, 2021 |
/s/ Anilu Vazquez-Ubarri |
Signature |
Exhibit 99.2
Consent to be Named as a Director Nominee
In connection with the filing by TPG Pace Beneficial II Corp. of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of TPG Pace Beneficial II Corp. in the Registration Statement and any and all amendments and supplements thereto. I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.
Dated: March 8, 2021 |
/s/ Mark Fields |
Signature |
Exhibit 99.3
Consent to be Named as a Director Nominee
In connection with the filing by TPG Pace Beneficial II Corp. of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of TPG Pace Beneficial II Corp. in the Registration Statement and any and all amendments and supplements thereto. I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.
Dated: March 8, 2021 |
/s/ Maryanne Hancock |
Signature |
Exhibit 99.4
Consent to be Named as a Director Nominee
In connection with the filing by TPG Pace Beneficial II Corp. of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of TPG Pace Beneficial II Corp. in the Registration Statement and any and all amendments and supplements thereto. I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.
Dated: March 8, 2021 |
/s/ Chad Leat |
Signature |
Exhibit 99.5
Consent to be Named as a Director Nominee
In connection with the filing by TPG Pace Beneficial II Corp. of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of TPG Pace Beneficial II Corp. in the Registration Statement and any and all amendments and supplements thereto. I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.
Dated: March 8, 2021 |
/s/ Nancy Mahon |
Signature |
Exhibit 99.6
Consent to be Named as a Director Nominee
In connection with the filing by TPG Pace Beneficial II Corp. of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of TPG Pace Beneficial II Corp. in the Registration Statement and any and all amendments and supplements thereto. I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.
Dated: March 8, 2021 |
/s/ Kneeland Youngblood |
Signature |